


## Supplementary figures

**A**




**B**


### 11 matched unique peptides to SRSF11

R.TLFGFLGK.I  
R.TLFGFLGKIDELR.L  
K.IDELRLFPPDDSPVSSR.V  
K.IDELRLFPPDDSPVSSRVCFVK.F  
R.LFPPDDSPVSSR.V  
R.LFPPDDSPVSSRVCFVK.F  
R.VCFVKFHDPDSAVVAQHLTNTVFVDR.A  
K.FHDPDSAVVAQHLTNTVFVDR.A  
R.ALIVVPYAEGVIPDEAK.A  
K.LMSTVDPKLNHVAAGLVSPSLK.S  
R.EAQLISAAIEPDKKEEK.R


**Supplementary Figure S1.** Identification of SRSF11 as a TERC-interacting protein by nano-liquid chromatography-tandem mass spectrometry (nano LC-MS/MS). **(A)** RNA affinity purification of TERC complexes from HeLa S3 cells identified multiple unique peptides for SRSF11 by nano LC-MS/MS. Diagram of SRSF11 protein shows location of unique peptides. RRM, RNA recognition motif; RS, arginine and serine-rich domain. **(B)** Eleven SRSF11 peptides from mass spectrometry are shown.




**Supplementary Figure S2.** SRSF11 association with TERT is RNase A-sensitive. **(A)** Lysates from HeLa S3 cells were immunoprecipitated with anti-SRSF11 antibody, followed by immunoblotting with anti-TERT antibody and quantitative RT-PCR to detect TERC. The extracts were treated with 0.1 mg/ml DNase I, 50  $\mu$ g/ml ethidium bromide (EtBr), and 0.1 mg/ml RNase A during immunoprecipitation. IgG was used as a negative control. **(B)** Lysates from telomerase-negative U2OS cells expressing Flag-TERT were immunoprecipitated with anti-Flag antibody, followed by immunoblotting with anti-SRSF11, anti-dyskerin, anti-TCAB1, and anti-Flag antibodies.




**Supplementary Figure S3.** Removing the TERC-binding domain (TRBD) on TERT abolishes SRSF11 association and TERC binding. **(A)** Schematic representation of mutant construct of hTERT in which the TERC-binding domain was deleted (TERTΔTRBD). **(B)** Lysates from HeLa S3 cells expressing Flag-TERT or TERTΔTRBD were immunoprecipitated with anti-Flag antibody, followed by immunoblotting with anti-SRSF11 antibody and quantitative RT-PCR to detect TERC.




**Supplementary Figure S4.** The shelterin components co-localize to nuclear speckles. HeLa S3 cells were analyzed by indirect immunofluorescence for co-localization of the various shelterin components with SC35 (nuclear speckle marker). Co-localization channels were calculated using Meta Imaging Series<sup>®</sup> MetaMorph software and appear in white in all figures. DNA was stained with DAPI. Coloc, co-localization.




**Supplementary Figure S5.** TERC co-localizes to nuclear speckles during S phase in telomerase-positive cells. Telomerase-positive H1299 and MCF7 cells and telomerase-negative U2OS and Saos-2 cells were synchronized in mid/late S phase and analyzed by indirect immunofluorescence for co-localization of TERC with SC35. Co-localization channels were calculated using Meta Imaging Series<sup>R</sup> MetaMorph software and appear in white in all figures. DNA was stained with DAPI. Coloc, co-localization.



**Supplementary Figure S6.** Telomeres localize to nuclear speckles after depletion of SRSF11. **(A)** HeLa S3 cells expressing control shRNA (shControl) or SRSF11 shRNAs (shSRSF11-1 and shSRSF11-2) were analyzed by indirect immunofluorescence for co-localization of SC35 with telomeric sites marked by TTAGGG-specific FISH probe. Co-localization channels were calculated using Meta Imaging Series<sup>R</sup> MetaMorph software and appear in white in all figures. DNA was stained with DAPI. Coloc, co-localization. **(B)** The average percentage of telomere foci co-localizing with SC35 per cell and standard deviation were determined by analyzing >100 nuclei.




**Supplementary Figure S7.** The levels of TERT mRNA and  $\beta$ -deletion transcript were not significantly changed upon depletion or overexpression of SRSF11. **(A)** Schematic representation of full-length TERT mRNA and  $\beta$ -deletion transcript. Primers for quantitative RT-PCR analysis are indicated by a pair of arrowheads and reveal a 333-bp fragment from full-length TERT mRNA and a 150-bp fragment from  $\beta$ -deletion transcript. **(B)** HeLa S3 cells expressing control shRNA (shControl) or SRSF11 shRNA (shSRSF11-1 and shSRSF11-2) were subjected to quantitative RT-PCR to measure the levels of TERT variant mRNAs and immunoblotting with anti-SRSF11 antibody. **(C)** HeLa S3 cells expressing shControl or shSRSF11 were analyzed for telomerase activity by the TRAP assay. ITAS, internal telomerase assay standard. **(D)** HeLa S3 cells expressing the empty vector or Myc-SRSF11 were subjected to quantitative RT-PCR to measure the levels of TERT variant mRNAs and immunoblotting with anti-SRSF11 antibody. **(E)** HeLa S3 cells expressing the empty vector or Myc-SRSF11 were analyzed for telomerase activity by the TRAP assay. ITAS, internal telomerase assay standard.





**Supplementary Figure S8.** The levels of full-length tau mRNA and exon 10-deleted tau mRNA were measured upon depletion or overexpression of SRSF11. **(A)** Schematic representation of full-length tau mRNA and exon 10-deleted tau mRNA. Primers for quantitative RT-PCR analysis are indicated by a pair of arrowheads and reveal a 280-bp fragment from full-length tau mRNA and a 187-bp fragment from exon 10-deleted tau mRNA. **(B)** HeLa S3 cells expressing control shRNA (shControl) or SRSF11 shRNA (shSRSF11-1 and shSRSF11-2) were subjected to quantitative RT-PCR to measure the levels of tau variant mRNAs. **(C)** Graphical representation of the relative levels of exon 10-deleted tau mRNA normalized against full-length tau mRNA. The mRNA levels were quantified with the average and standard deviation from three independent experiments. **(D)** HeLa S3 cells expressing the empty vector or Myc-SRSF11 were subjected to quantitative RT-PCR to measure the levels of tau variant mRNAs. **(E)** Graphical representation of the relative levels of exon 10-deleted tau mRNA normalized against full-length tau mRNA.








**Supplementary Figure S9.** SRSF11 interacts with TRF2 irrespective of cell cycle phase. **(A)** HeLa S3 cells expressing Flag-SRSF11 and TRF2-V5 were synchronized in mid/late S phase and subjected to immunoprecipitation with Flag-antibody, followed by immunoblotting with anti-V5 antibody. Immunoblot for proliferation cell nuclear antigen (PCNA) was used for an independent marker of S phase. AS, asynchronous cells. **(B)** HeLa S3 cells were synchronized in mid/late S phase and analyzed by indirect immunofluorescence for co-localization of SRSF11 with TRF2. Co-localization channels were calculated using Meta Imaging Series<sup>R</sup> MetaMorph software and appear in white in all figures. DNA was stained with DAPI. Coloc, co-localization. **(C)** The average percentage of TRF2 foci co-localizing with SRSF11 per cell and standard deviation were determined by analyzing >100 nuclei for each cell cycle phase.

**A****B**

**Supplementary Figure S10.** Identification of the domain in SRSF11 that is required for TRF2 binding. **(A)** HeLa S3 cells were co-transfected with Myc-TRF2 and Flag-SRSF11, Flag-RRM, or Flag-RS and subjected to immunoprecipitation with anti-Flag antibody, followed by immunoblotting with anti-Myc antibody. The asterisk marks the position of nonspecific immunoglobulin chains. **(B)** Subcellular localization of the SRSF11 deletion mutants, RRM and RS. HeLa S3 cells were transfected with Myc-RRM or Myc-RS and analyzed by indirect immunofluorescence for co-localization of RRM or RS with SC35. DNA was stained with DAPI.



**Supplementary Figure S11.** Depletion of TRF2 has no effect on co-localization of telomeres with nuclear speckles. **(A)** HeLa S3 cells expressing control shRNA (shControl) or TRF2 shRNAs (shTRF2-1 and shTRF2-2) were subjected to immunoblotting to measure the levels of endogenous TRF2 and SRSF11. **(B)** HeLa S3 cells expressing shControl or shTRF2 were analyzed by indirect immunofluorescence for co-localization of SRSF11 with telomeric sites marked by TTAGGG-specific FISH probe. DNA was stained with DAPI. **(C)** The average percentage of telomere foci co-localizing with SRSF11 per cell and standard deviation were determined by analyzing >100 nuclei. **(D)** HeLa S3 cells expressing shControl or shTRF2 were analyzed by indirect immunofluorescence for co-localization of SC35 with telomeric sites marked by TTAGGG-specific FISH probe. DNA was stained with DAPI. **(E)** The average percentage of telomere foci co-localizing with SC35 per cell and standard deviation were determined by analyzing >100 nuclei.

**A****B**

**Supplementary Figure S12.** Telomerase recruitment to telomeres by SRSF11 precedes TPP1. **(A)** HeLa S3 cells expressing control shRNA (shControl) or SRSF11 shRNAs (shSRSF11-1 and shSRSF11-2) were subjected to immunoprecipitation with anti-TPP1 antibody, followed by immunoblotting with anti-TERT antibody. IgG was used as a negative control. The asterisk marks the position of nonspecific immunoglobulin chains. **(B)** HeLa S3 cells expressing shControl or shSRSF11 were subjected to immunoprecipitation with anti-TPP1 antibody. Immunoprecipitates of endogenous TPP1 were analyzed for telomerase activity by the TRAP assay. ITAS, internal telomerase assay standard.